| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Scherle Peggy is a Chief Scientific Officer at Prelude Therapeutics Inc. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $773K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 7,714 | $35.75 | $275,786.75 | -1.1% | -62.7% | -79.3% | |
| Aug 13, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 2,286 | $35.07 | $80,161.33 | -1.3% | -47.9% | -73.0% | |
| Jul 27, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 20,000 | $35.47 | $709,379.88 | -5.5% | -49.1% | -83.0% | |
| May 7, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 10,000 | $40.82 | $408,192.28 | -1.9% | -22.1% | -89.7% | |
| Apr 8, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 4,630 | $38.34 | $177,503.90 | -0.7% | -28.6% | -82.4% | |
| Apr 7, 2021 | PRLD Prelude Therapeutics Inc | Chief Scientific Officer | Sale+OE | 15,370 | $39.31 | $604,144.17 | -2.8% | -31.2% | -81.8% |